NCT04758052

Brief Summary

There is currently no prospective study analyzing the effect of tracheostomy with bedside simultaneous gastrostomy versus tracheostomy with delayed gastrostomy placement (TSG versus TDG) on the outcomes of neurocritically-ill patients. The investigators will study TSG via concomitant PDT and PUG procedures, while TDG will occur per usual care. This study is a prospective randomized open-label blinded endpoint study to assess the effect of tracheostomy with bedside simultaneous gastrostomy (TSG) versus the usual care of tracheostomy with delayed gastrostomy (TDG) placement on outcomes of neurocritically-ill patients.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2021

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 4, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 17, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

March 31, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2022

Completed
Last Updated

June 9, 2021

Status Verified

June 1, 2021

Enrollment Period

9 months

First QC Date

February 4, 2021

Last Update Submit

June 5, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • ICU length of stay

    total number of midnights a patient is in the ICU for the duration of their hospital stay

    during hospital stay, assessed up to 10 days

Secondary Outcomes (10)

  • hospital length of stay

    during hospital stay, assessed up to 10 days

  • nutritional metrics

    up to 14 days before the procedure and up to 14-days before discharge

  • procedural analgo-sedation used

    intraprocedure

  • all-cause mortality

    during hospital stay, assessed up to 10 days

  • swallow function return

    during hospital stay, assessed up to 10 days

  • +5 more secondary outcomes

Study Arms (2)

simultaneous tracheostomy with gastrostomy (TSG)

EXPERIMENTAL

This arm include the patients assigned to placement of gastrostomy immediately after tracheostomy.

Other: Timing of placement

non-simultaneous or delayed approach tracheostomy and gastrostomy (TDG)

NO INTERVENTION

This arm include the patients who proceed with "usual care" placement of tracheostomy and gastrostomy as per Neurocritical care Unit service standard.

Interventions

Simultaneous placement of tracheostomy and gastrostomy

simultaneous tracheostomy with gastrostomy (TSG)

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old- 85 years old
  • Admitted under the NSICU service
  • Shared-decision making with surrogate decision maker and primary neuro-intensivist agreement to proceed with tracheostomy and gastrostomy with documented discussion.
  • have indications for tracheostomy and gastrostomy
  • Subjects or their SDM or legally authorized representative (LARs) must voluntarily provide informed consent prior to the initiation of any study-specific procedure in a form approved by an independent IRB. In the absence of subject's ability to provide informed consent, informed consent must be given by a person who has the legal right to act on behalf of the subject in accordance with local laws.

You may not qualify if:

  • Patients who require tracheostomy only or gastrostomy only
  • history of prior gastrostomy, tracheostomy, laryngectomy, gastrostomy prior to tracheostomy decision, known head and neck and gastrointestinal abnormality (cancer, congenital abnormality, anatomic variants)
  • withdrawal of care, a transfer from another service or hospital if patient has been there for \>24hr.
  • known social discharge issues anticipating hospital stay \>100 days
  • Patients with nonsurvivable injuries, anticipated mortality \<72 hours
  • standard of care contraindications for either bedside tracheostomy and gastrostomy
  • Absolute contraindications for gastrostomy: gastric outlet obstruction, significant gastroparesis, significant gastroesophageal reflux, a proximal high-output entercutaneous fistula
  • Standard Contraindications for percutaneous gastrostomy technique: ascites, morbid obesity and esophageal and gastric pathology
  • Standard Contraindications for either PEG or PUG procedures
  • Standard Contraindications to percutaneous dilational tracheostomy: Gross anatomical distortion of the neck, previous neck surgery , burns, radiotherapy, unstable or rigid cervical spine, tracheal distortion, stenosis, or malacia, morbid obesity (BMI \>35kg/m2), massive thyroid gland or vessels in the operation field on ultrasound, hemodynamic instability, refractory intracranial hypertension, hemodynamic instability, Coagulopathy (Aptt\>50s, INR\>1.5, platelet count \<50,000μL, emergency need for a tracheostomy or need for a permanent tracheostoma, very difficult airway management
  • Pregnancy
  • Life expectancy less than three-weeks
  • Goals of care disagreement between care team and LAR
  • braindead
  • LAR preferred procedures placed in LTAC

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Christa O'Hana S. Nobleza

Jackson, Mississippi, 39216, United States

Location

MeSH Terms

Conditions

StrokeNeuromuscular DiseasesStatus EpilepticusComaCerebrovascular DisordersSpinal Cord InjuriesTrauma, Nervous System

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesSeizuresNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsUnconsciousnessConsciousness DisordersNeurobehavioral ManifestationsSpinal Cord DiseasesWounds and Injuries
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
blinded endpoint
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: single-center prospective randomized open-label blinded endpoint proof-of-concept study to assess the effect of TSG versus usual care TDG placement on outcomes among neurocritically-ill patients.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 4, 2021

First Posted

February 17, 2021

Study Start

March 31, 2021

Primary Completion

January 1, 2022

Study Completion

August 1, 2022

Last Updated

June 9, 2021

Record last verified: 2021-06

Locations